Adaptimmune Therapeutics plc (NASDAQ:ADAP) has a beta value of 2.17 and has seen 1.34 million shares traded in the last trading session. The company, currently valued at $768.02M, closed the last trade at $4.94 per share which meant it lost $0.0 on the day or 0.00% during that session. The ADAP stock price is -121.26% off its 52-week high price of $10.93 and 31.78% above the 52-week low of $3.37. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.27 million shares traded. The 3-month trading volume is 827.08K shares.
The consensus among analysts is that Adaptimmune Therapeutics plc (ADAP) is a Hold stock at the moment, with a recommendation rating of 2.70. 1 analysts rate the stock as a Sell, while 0 rate it as Overweight. 4 out of 8 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -$0.24.
Adaptimmune Therapeutics plc (NASDAQ:ADAP) trade information
Sporting 0.00% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on Friday, 09/03/21 when the ADAP stock price touched $4.94 or saw a rise of 8.86%. Year-to-date, Adaptimmune Therapeutics plc shares have moved -8.35%, while the 5-day performance has seen it change -4.08%. Over the past 30 days, the shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP) have changed 39.94%. Short interest in the company has seen 3.93 million shares shorted with days to cover at 3.99.
Wall Street analysts have a consensus price target for the stock at $9.33, which means that the shares’ value could jump 47.05% from current levels. The projected low price target is $4.00 while the price target rests at a high of $17.00. In that case, then, we find that the current price level is -244.13% off the targeted high while a plunge would see the stock lose 19.03% from current levels.
Adaptimmune Therapeutics plc (ADAP) estimates and forecasts
Figures show that Adaptimmune Therapeutics plc shares have underperformed across the wider relevant industry. The company’s shares have gained 0.82% over the past 6 months, with this year growth rate of -16.67%, compared to 7.50% for the industry. Revenue growth from the last financial year stood is estimated to be 45.80%.
7 analysts offering their estimates for the company have set an average revenue estimate of $3.1 million for the current quarter. 8 have an estimated revenue figure of $1.35 million for the next quarter concluding in Sep 2021. Year-ago sales stood $930k and $1.19 million respectively for this quarter and the next, and analysts expect sales will grow by 232.80% for the current quarter and 13.20% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -24.90% over the past 5 years. Earnings growth for 2021 is a modest 30.10% while over the next 5 years, the company’s earnings are expected to increase by 1.00%.
Adaptimmune Therapeutics plc is expected to release its next earnings report on May 06 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Adaptimmune Therapeutics plc (NASDAQ:ADAP)’s Major holders
Insiders own 0.12% of the company shares, while shares held by institutions stand at 77.31% with a share float percentage of 77.41%. Investors are also buoyed by the number of investors in a company, with Adaptimmune Therapeutics plc having a total of 105 institutions that hold shares in the company. The top two institutional holders are Matrix Capital Management with over 38.97 million shares worth more than $206.95 million. As of Mar 30, 2021, Matrix Capital Management held 25.07% of shares outstanding.
The other major institutional holder is NEA Management Company, LLC, with the holding of over 17.08 million shares as of Mar 30, 2021. The firm’s total holdings are worth over $90.71 million and represent 10.99% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Smallcap World Fund and Old Westbury Small & Mid Cap Strategies Fund. As of Mar 30, 2021, the former fund manager holds about 6.00% shares in the company for having 9.32 million shares of worth $49.51 million while later fund manager owns 1.77 million shares of worth $9.68 million as of Jan 30, 2021, which makes it owner of about 1.14% of company’s outstanding stock.